Gilead Sciences, Inc. vs VICI Properties Inc — how do they compare? Gilead Sciences, Inc. trades at $135.41 (market cap $168.35B), while VICI Properties Inc trades at $25.99 (market cap $28.61B). The key difference: Gilead Sciences, Inc. is far larger — about 5.9× VICI Properties Inc's market cap, and VICI Properties Inc pays the higher dividend (6.93%). Which is the better fit depends on your goals.
| GILD | VICI | |
|---|---|---|
Market Cap | $168.35B | $28.61B |
Sector | Health | Real Estate |
52-Week High | $155.80 | $33.78 |
52-Week Low | $110.56 | $25.94 |
Enterprise Value | $191.42B | $46.16B |
Dividend Yield | 2.42% | 6.93% |
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →